Clinical Trials Logo

Filter by:
NCT ID: NCT00688896 Completed - Clinical trials for Type II Hyperlipidemia

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Start date: June 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of two dose levels of JTT-705 when co-administered with pravastatin 40 mg on HDL-C and LDL-C and the inhibition rate of CETP activity and to document short term safety.

NCT ID: NCT00688688 Completed - Clinical trials for Urinary Bladder, Overactive

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

TAURUS
Start date: April 25, 2008
Phase: Phase 3
Study type: Interventional

The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.

NCT ID: NCT00688623 Completed - Carcinoma Clinical Trials

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe

RAMSETE/CDE16
Start date: June 24, 2009
Phase: Phase 2
Study type: Interventional

To evaluate the preliminary efficacy and safety of RAD001 as monotherapy for first-line treatment of patients with metastatic papillary carcinoma of the kidney.

NCT ID: NCT00688571 Completed - Clinical trials for Heart Valve Diseases

Melody Transcatheter Pulmonary Valve (TPV) Post-Market Surveillance Study

Start date: October 2007
Phase: N/A
Study type: Interventional

This non-randomized, prospective, interventional observational multi-center study is designed to assess the long-term clinical performance of the Medtronic Melody™ Transcatheter Pulmonary Valve (TPV) in the post market environment over a period of five years after transcatheter implantation in patients with dysfunctional RVOT conduits. In addition, the quality of life of implanted subjects will be assessed over five years.

NCT ID: NCT00688558 Completed - Dyslipidemia Clinical Trials

Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate safety of JTT-705 and to demonstrate efficacy of JTT-705 compared with placebo when co-administered with simvastatin 40 mg in patients with low HDL

NCT ID: NCT00688376 Completed - Clinical trials for Attention Impairment

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

Start date: July 2, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment.

NCT ID: NCT00688077 Completed - Hypophosphatemia Clinical Trials

FGF-23 Suppressibility by Calcitonin

Start date: May 2008
Phase: N/A
Study type: Interventional

Introduction: Based on our experience with calcitonin as an FGF-23 suppressive agent in a patient with an FGF-23 producing tumor we hypothesize that calcitonin may be a physiologically important regulator of FGF-23 production and secretion in healthy humans. Aim: In this study we wish to examine the FGF-23 suppressive effects of calcitonin in healthy men. Study Design: placebo-controlled, cross-over study Method: - All twelve subjects are examined on two occasions, once after exposure to placebo 1 ml NaCl 0.9% subcutaneously, and once following calcitonin 200 IU/ml subcutaneously - On both occasions frequent bloodsampling will take place, out an indwelling catheter in de forearm vein. - Sampling times: -15, 0, 60, 120, 240, 360, and 480 minutes - Mealtimes: Calcium and Phosphate intake standardized on both occasions - All samples are analyzed for FGF-23, using a C-terminal FGF-23 ELISA kit (Immunotopics, San Clemente, USA) that measures intact and C-terminal fragments of FGF-23, and one that measures only intact FGF-23 - Samples obtained at T-15, T0, T240 and T480 are stored for later analysis of Ca, albumin, PO4, PTH, 25-OHD and 1,25-OHD Endpoint: A change of 25% in de serum FGF-23 levels in response to a single subcutaneous injection of calcitonin 200 IU.

NCT ID: NCT00687882 Completed - Venous Thrombosis Clinical Trials

Evaluation of the Duration of Therapy for Thrombosis in Children

Kids-DOTT
Start date: March 2008
Phase: Phase 3
Study type: Interventional

The Kids-DOTT trial is a randomized controlled clinical trial whose primary objective is to evaluate non-inferiority of shortened-duration (6 weeks) versus conventional-duration (3 months) anticoagulation in children with first-episode acute venous thrombosis. The first stage of the trial has consisted of a pilot/feasibility component, which then continues as the definitively-powered trial.

NCT ID: NCT00687804 Completed - Clinical trials for Diabetic Macular Edema

A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study

RESTORE
Start date: May 2008
Phase: Phase 3
Study type: Interventional

CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to diabetic macular edema. CRFB002D2301E1: A 24 month open-label extension study for participants who completed the 12 month core study evaluated the long-term safety and efficacy of ranibizumab (0.5 mg) as symptomatic treatment for visual impairment due to diabetic macular edema.

NCT ID: NCT00686959 Completed - Clinical trials for Non Small Cell Lung Cancer

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

PROCLAIM
Start date: September 2008
Phase: Phase 3
Study type: Interventional

This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.